• 10074-G5: c-Myc Inhibitor Workflows for Cancer Research Succ

  2026-04-27

  10074-G5 empowers cancer researchers to dissect c-Myc-driven pathways with precision, enabling robust apoptosis and tumor regression studies. This article maps evidence-backed protocols, troubleshooting tips, and translational insights to maximize workflow reproducibility and scientific impact.

• mRNA Nanovaccine Targeting GPC3 in HCC: Immune Synergy Insig

  2026-04-27

  This study introduces a novel mRNA nanovaccine encoding a GPC3-HSP70 fusion antigen for hepatocellular carcinoma (HCC), demonstrating robust T-cell-mediated immune responses. When combined with anti-PD-L1 therapy, this strategy shows potent synergistic antitumor efficacy, offering a promising direction for HCC immunotherapy.

• Cy5-UTP for RNA Labeling: Enhanced Workflows and Real-World

  2026-04-26

  Cy5-UTP (Cyanine 5-uridine triphosphate) empowers molecular biologists with robust, direct RNA labeling, enabling streamlined probe synthesis and high-sensitivity detection for FISH, dual-color arrays, and advanced transcriptomics. This guide details optimized workflows, protocol parameters, and troubleshooting strategies to maximize performance and reproducibility with APExBIO's Cy5-UTP.

• Necrostatin-1: Strategic RIP1 Inhibition for Translational R

  2026-04-25

  This article provides translational researchers with a strategic blueprint for leveraging Necrostatin-1 (Nec-1) as a selective RIP1 kinase inhibitor in necroptosis research. Blending mechanistic insight with workflow guidance, it contextualizes recent advances in adipose tissue biology, inflammatory injury, and metabolic disease, and clarifies how APExBIO’s Nec-1 product enables robust, reproducible investigation of cell death pathways. The discussion goes beyond standard product pages by connecting emerging evidence, protocol parameters, and competitive positioning, culminating in a forward-looking outlook for preclinical and clinical translation.

• GPR107 Deficiency Drives Diabetic Nephropathy via AT1R Signa

  2026-04-24

  Xu et al. elucidate a mechanism by which GPR107 deficiency in podocytes exacerbates diabetic nephropathy (DN), demonstrating that impaired clathrin-mediated AT1 receptor internalization leads to increased collagen IV accumulation and glomerular damage. This research identifies GPR107 as a potential therapeutic target and clarifies the interplay between endocytosis, angiotensin II signaling, and extracellular matrix remodeling in DN.

• Endothelial Endoglin Drives Astrocyte Reactivity in Alzheime

  2026-04-24

  This study uncovers how endothelium-derived endoglin (ENG) is transferred via extracellular vesicles to astrocytes, activating inflammatory pathways and contributing to Alzheimer’s disease (AD) pathology. The findings redefine the role of cerebrovascular dysfunction in AD and establish ENG as a mechanistic link and potential therapeutic target.

• Alda 1: ALDH2 Activator for Cardiac Ischemia & Dermatitis Mo

  2026-04-23

  Alda 1 stands out as a powerful ALDH2 activator, enabling breakthrough workflows in cardiac ischemia research and radiation-induced dermatitis mitigation. Explore its mechanistic strengths, protocol optimizations, and evidence-backed troubleshooting strategies for advanced experimental outcomes.

• Cyanine 3 Tyramide: Fluorescent Dye for Biomedical Research

  2026-04-23

  Cyanine 3 Tyramide empowers researchers to detect low-abundance targets in complex tissues with unrivaled sensitivity, especially in immunohistochemistry and in situ hybridization. This APExBIO reagent delivers robust signal amplification, making it a leading choice for advanced neurobiology and molecular labeling workflows.

• Cofilin Activation Drives CCK-Stimulated Pancreatic Secretio

  2026-04-22

  This study reveals that cofilin activation is essential for CCK-stimulated enzyme secretion and growth in pancreatic acinar cells, identifying a convergent signaling node independent of classic kinase pathways. The findings refine understanding of actin dynamics in exocrine pancreas physiology and provide a mechanistic foundation for future inflammation and cancer therapeutics research.

• Targeting AGTR1 in Armored Tumors to Enhance Immunotherapy R

  2026-04-22

  This study systematically identifies angiotensin II receptor 1 (AGTR1) as a key biomarker and therapeutic target in 'armored and cold' tumors, which are typically refractory to immune checkpoint blockade (ICB). By demonstrating that angiotensin II receptor antagonists can remodel the tumor microenvironment and sensitize these tumors to ICB, the work offers a mechanistically informed approach for combination cancer therapies.

• TP53-Dependent Antitumor Action of DHODH Inhibition in NPC

  2026-04-21

  Dong et al. demonstrate that targeting dihydroorotate dehydrogenase (DHODH) potently inhibits nasopharyngeal carcinoma (NPC) cell growth via TP53 activation. This work establishes the significance of nucleic acid metabolism reprogramming in NPC and highlights a promising, TP53-dependent therapeutic strategy.

• AT13387 and Hsp90 Inhibition: Next-Gen Strategies for Transl

  2026-04-21

  This thought-leadership article explores the mechanistic and translational frontiers of AT13387, a potent Hsp90 inhibitor, in cancer biology research. Synthesizing new evidence from apoptosis regulation and DAMP release, it offers strategic guidance for translational researchers seeking to realize the full potential of Hsp90 chaperone inhibition in advanced oncology workflows.

• Cisplatin (CDDP): Mechanistic Benchmarks and Research Utilit

  2026-04-20

  Cisplatin is a platinum-based chemotherapy agent with potent DNA crosslinking and apoptosis-inducing activity. It remains a crucial tool in cancer research for studying tumor cell death, chemoresistance, and oxidative stress responses. This article clarifies cisplatin's molecular mechanisms, benchmarks, and workflow integration with direct, evidence-based claims.

• Lenalidomide (CC-5013): Reliable Solutions for Cancer Resear

  2026-04-20

  This GEO-driven guide explores real laboratory challenges in cell viability and multiple myeloma research, showing how Lenalidomide (CC-5013), SKU A4211, provides reproducible, literature-backed solutions. Scenario-based Q&A address assay optimization, immune modulation, and product reliability—grounded in peer-reviewed data and practical workflows.

• Ionizing Radiation Alters Neuronal Differentiation via PI3K-

  2026-04-19

  This study demonstrates that ionizing radiation (IR) promotes altered neuronal differentiation in C17.2 mouse neural stem-like cells by activating PI3K-STAT3-mGluR1 and PI3K-p53 signaling pathways. The findings advance our understanding of IR-induced neurogenic changes, offering mechanistic insight into potential late effects of brain radiotherapy.

449 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page